Demerger information
Documents relating to the Demerger:
Shareholders can view the Prospectus in relation to the admission of the Haleon plc ordinary shares along with associated documents via the links below.
- Prospectus
- Articles of Association of Haleon plc
- Deloitte’s written consent letter
- Deloitte’s report on the Unaudited Pro Forma Financial Information of the Group
- Deloitte’s report on the Historical Financial Information of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited
- Deloitte’s report on the Pfizer Historical Financial Information
Shareholder FAQs
A comprehensive list of shareholder FAQs relating to the Demerger can be found on the shareview website. If you have any additional questions, feel free to contact our Registrars, Equiniti Limited via one of the methods below:
Online contact form: Get Help From The EQ Team - Equiniti
Equiniti Limited shareholder helpline: +44 (0) 371 384 2227
Calls to this number are charged at 8p per minute from a BT landline. Other telephony providers' costs may vary.
or by writing to:
Equiniti Limited Aspect House Spencer Road Lancing West Sussex BN99 6DA